|
|
|
|
|
|
|
|
|
|
financial media
This Small-Cap Cancer Immunotherapy Developer Just Snagged Another Big Partner
.... As announced on Monday in a press release, Peregrine and AstraZeneca will explore their respective cancer immunotherapies -- PS-suppressor bavituximab and anti-PD-L1 checkpoint inhibitor MEDI4736 from AstraZeneca -- in various solid tumor types in a phase 1/1b trial. The phase 1 portion will focus on dose-finding, while phase 1b will examine the safety and efficacy of the combination therapy. Under the terms of the agreement, Peregrine will run the initial study....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.